This study identifies circCRIM1 as a new tumor suppressor that inhibits tumor immune evasion through a competitive combination with IGF2BP1 to destabilize HLA-F mRNA.
Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion.